Summary of Bioventus Inc. Q3 2025 Earnings Call

1Key Financial Results and Metrics

Revenue: $139 million, reflecting an 8% organic growth, an acceleration from the first half of the year.

Adjusted EBITDA: Increased by 13% to $27 million, with an adjusted EBITDA margin expanding by over 200 basis points to 19%.

Adjusted Earnings Per Share: $0.15, a 200% increase compared to the prior year.

Cash Flow: Cash from operations nearly tripled year-over-year to $30 million, with a cash conversion ratio exceeding 100%.

Debt: Reduced by $19 million, with a net leverage ratio below 3x, expected to drop below 2.5x by year-end.

2Strategic Updates and Business Highlights

Growth Drivers: Strong performance in pain treatments, surgical solutions, and restorative therapies. Notable growth in HA therapies, particularly DUROLANE, and in the surgical solutions segment, especially bone graft substitutes.

New Product Launches: Successful limited launch of peripheral nerve stimulation (PNS) products and the Excel platelet-rich plasma (PRP) system, with positive feedback from customers.

Market Positioning: Focus on expanding market share in high-growth areas, with expectations for continued growth in pain treatments and surgical solutions.

3Forward Guidance and Outlook

2025 Financial Guidance: Reaffirmed organic revenue growth of 6% to 8%, adjusted EBITDA between $112 million and $116 million, and EPS of $0.64 to $0.68.

Future Growth: Anticipation of continued momentum into 2026, with a focus on PNS and PRP as significant growth drivers.

4Challenges and Points of Concern

Divestiture Impact: Revenue from restorative therapies declined by 29% due to the divestiture of the advanced rehabilitation business, though organic growth was 11% excluding this impact.

Foreign Exchange Losses: Experienced unplanned losses of nearly $0.5 million due to foreign currency fluctuations, with a total impact of over $2.5 million year-to-date.

Market Competition: Ongoing price pressure in the HA market, particularly for legacy products, could affect growth.

5Notable Q&A Insights

Pain Treatments: DUROLANE is driving growth, with the company focused on maintaining volume above market growth despite fluctuations.

Surgical Solutions: Anticipated acceleration in Q4, supported by strong distributor performance and the value proposition of their products.

Commercial Execution: Emphasis on scaling the commercial organization for new products like TalisMann, with plans for increased market awareness and education.

Profitability and Growth Balance: Management is committed to expanding margins while investing in growth opportunities, particularly in ultrasonics and international markets. Overall, Bioventus showcased a solid performance in Q3 2025, with strong revenue growth and profitability metrics, while also addressing challenges related to market competition and the impact of divestitures. The company remains optimistic about its growth trajectory and strategic initiatives moving forward.